EGFR and non-small cell lung carcinoma: Approximately 10% of patients with non-small cell lung cancer (NSCLC) (those harboring an activating mutation of EGFR) show a dramatic shrinkage in response to the inhibitor gefitinib [39], [40], but this is unlikely to lead to long-term cure.